Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Ltd (ASX: IMRN) provides investors and industry stakeholders with timely updates through this centralized news resource. Track the Australian biopharmaceutical innovator's progress in developing oral immunotherapies targeting gastrointestinal and immune-mediated disorders.
Access verified announcements covering clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection includes updates on Immuron's hyperimmune bovine colostrum platform, product pipeline advancements, and financial disclosures - all essential for understanding the company's position in the immunotherapy sector.
Key focus areas include Travelan® commercialization efforts, research into non-alcoholic fatty liver disease treatments, and novel applications of polyclonal antibody technology. Bookmark this page for efficient monitoring of Immuron's progress in addressing unmet needs across gastroenterology and immunology markets.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced the resignation of Peter Anastasiou, effective immediately. Anastasiou, who joined the Board in 2015 and served as Vice Executive Chairman, cited the missed opportunity to invest in a significant Covid vaccine asset as a reason for his departure. Despite this, he expressed confidence in the company's technology and financial standing. The Board commended Anastasiou for his contributions, stating that the company has a strong cash reserve and an exciting project pipeline.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced the termination of its proposed acquisition of a private biotechnology firm focused on vaccine development due to ASX regulatory concerns. The planned acquisition, aimed at enhancing shareholder value and providing a COVID-19 vaccine candidate, was deemed infeasible as the ASX did not find sufficient information to meet its listing requirements. Consequently, Immuron will resume trading from September 24, 2021, and incur approximately $450k in professional fees related to this unsuccessful endeavor.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced a research update on its SARS-CoV-2 program in collaboration with Monash University's Biomedicine Discovery Institute. The study focuses on IMM-124E, showing potential inhibitory activity against the virus, distinct from current vaccine approaches. This suggests a complementary therapeutic option. Additionally, Dr. Dan Peres has been appointed as Chief Medical Officer to lead clinical programs, primarily targeting COVID-19.
Immuron Limited has announced the recommencement of its IMM-124E IND Program and a clinical study for Travelers' Diarrhea (TD) in collaboration with the Uniformed Services University. The Phase III clinical trial will assess the efficacy of nutraceutical products, including IMM-124E, in preventing TD for individuals traveling to high-risk regions. Additionally, the company has engaged Professor Teena Chopra to explore gastrointestinal issues linked to COVID-19, emphasizing their innovative, non-antibiotic solutions for gut health.
Immuron (ASX: IMC; NASDAQ: IMRN) announced the closing of a registered direct offering of 1,066,668 American Depositary Shares (ADSs) at $18.75 per ADS, totaling approximately $20 million in gross proceeds. The funds will be utilized for research and development, clinical programs, marketing for its flagship product Travelan, and general working capital. The offering was overseen by H.C. Wainwright & Co., and a registration statement was declared effective by the SEC. This offering aims to enhance the company's financial positioning and support its ongoing projects.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced a registered direct offering of 1,066,668 American Depositary Shares (ADSs) at $18.75 per ADS, expected to generate approximately $20.0 million in gross proceeds.
This funding will support clinical programs, enhance marketing for Travelan, and provide ongoing working capital. The offering is being managed by H.C. Wainwright & Co. and will close around July 23, 2020, subject to customary conditions.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced that its product, IMM-124E, has shown antiviral activity against SARS-CoV-2 in laboratory studies. Conducted by 360 biolabs, the study tested four production lots of IMM-124E, demonstrating effective concentrations (EC50 and EC90) that inhibit viral replication while maintaining cell viability. The findings suggest a potential new oral therapeutic approach targeting COVID-19 in the gastrointestinal tract. Immuron has filed a provisional patent application for these findings, indicating the significance of their research in response to the pandemic.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has received FDA guidance on a new oral therapeutic targeting Campylobacter and ETEC infections. Two Phase II clinical trials are set for 2021; one will assess protection against campylobacteriosis, while the other will focus on ETEC. The FDA meeting discussed manufacturing controls and planned studies to evaluate the therapeutic's safety and efficacy. The company is also progressing on its manufacturing program, with the second immunization campaign completed and colostrum harvesting scheduled for September, crucial for drug production.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced significant advancements in its research collaboration with the Naval Medical Research Center (NMRC) and CSIRO. The company signed a research agreement with CSIRO to develop a therapeutic targeting Campylobacter and ETEC for clinical evaluation. Furthermore, NMRC submitted a Pre-IND package to the FDA, anticipating comments within 30 days. A vaccination program has commenced, and two human phase II clinical trials are scheduled for 2021, focusing on protecting against campylobacteriosis and ETEC infections.
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced a collaboration with the Naval Medical Research Center (NMRC) focused on developing a new oral therapeutic targeting Campylobacter and ETEC infections. A Pre-IND meeting with the FDA has been requested, paving the way for Phase II clinical trials in 2021. The trials aim to evaluate the efficacy of the therapeutic in protecting against severe campylobacteriosis and ETEC infections. However, previous study results indicated negative findings in the IMM-124E pediatric trial for Nonalcoholic Fatty Liver Disease due to a small sample size.
